促甲状腺激素分泌型垂体腺瘤的全外显子组测序研究
该研究对12例散发性促甲状腺激素分泌型垂体腺瘤(TSH瘤)患者进行全外显子组测序和SNP阵列分析,发现6个候选驱动突变,平均每肿瘤1.5个体细胞突变,无复发性突变,提示TSH瘤良性本质,作者认为需更大队列及表观遗传和转录组学研究。
要点
- 12例散发性TSH瘤中,全外显子组测序平均覆盖97.6%,确认6个候选驱动突变。
- 平均每肿瘤1.5个体细胞突变,未发现复发性突变。
- SNP阵列显示频繁拷贝数增益,包括4个候选基因所在位点的复发性增益。
核心结论
- 研究鉴定了TSH瘤的若干候选体细胞突变和拷贝数变化,未发现复发性突变且突变数量低,突显其良性本质。
- 作者认为需在更大TSH瘤队列中进一步研究,并结合表观遗传和转录组学方法,才可能揭示潜在遗传病变。
研究设计与样本
- 对8例TSH瘤进行单核苷酸多态性(SNP)阵列分析,选择4例无等位基因丢失或杂合性丢失有限的肿瘤及其对应血样进行全外显子组测序,体细胞变异经Sanger测序确认,另用8例肿瘤验证候选基因。
- 共检查12例散发性TSH瘤患者。
主要发现
- 全外显子组测序总体表现良好,目标区域每个碱基平均覆盖度为97.6%。
- 确认6个DNA变异为候选驱动突变,平均每肿瘤1.5个体细胞突变,无复发性突变。
- 2个突变位于已知参与恶性肿瘤发生的基因(SMOX和SYTL3),4个位于功能未知基因(ZSCAN23、ASTN2、R3HDM2和CWH43)。
- SNP阵列分析显示频繁的染色体拷贝数增益区域,包括携带上述6个基因中4个的位点复发性增益。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为需在更大TSH瘤队列中进一步研究,并结合表观遗传和转录组学方法,才可能揭示潜在遗传病变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Thyrotropin (TSH)-secreting pituitary adenomas (TSHomas) are a rare cause of hyperthyroidism, and the genetic aberrations responsible remain unknown. OBJECTIVE: To identify somatic genetic abnormalities in TSHomas. DESIGN AND SETTING: A single-nucleotide polymorphism (SNP) array analysis was performed on 8 TSHomas. Four tumors with no allelic losses or limited loss of heterozygosity were selected, and whole-exome sequencing was performed, including their corresponding blood samples. Somatic variants were confirmed by Sanger sequencing. A set of 8 tumors was also assessed to validate candidate genes. PATIENTS: Twelve patients with sporadic TSHomas were examined. RESULTS: The overall performance of whole-exome sequencing was good, with an average coverage of each base in the targeted region of 97.6%. Six DNA variants were confirmed as candidate driver mutations, with an average of 1.5 somatic mutations per tumor. No mutations were recurrent. Two of these mutations were found in genes with an established role in malignant tumorigenesis (SMOX and SYTL3), and 4 had unknown roles (ZSCAN23, ASTN2, R3HDM2, and CWH43). Similarly, an SNP array analysis revealed frequent chromosomal regions of copy number gains, including recurrent gains at loci harboring 4 of these 6 genes. CONCLUSIONS: Several candidate somatic mutations and changes in copy numbers for TSHomas were identified. The results showed no recurrence of mutations in the tumors studied but a low number of mutations, thereby highlighting their benign nature. Further studies on a larger cohort of TSHomas, along with the use of epigenetic and transcriptomic approaches, may reveal the underlying genetic lesions.
引用
- Sapkota S, Horiguchi K, Tosaka M, et al. Whole-Exome Sequencing Study of Thyrotropin-Secreting Pituitary Adenomas. J Clin Endocrinol Metab. 2017. PMID: 27854551. doi:10.1210/jc.2016-2261
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。